Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017112741) MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/112741 International Application No.: PCT/US2016/067957
Publication Date: 29.06.2017 International Filing Date: 21.12.2016
IPC:
A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants:
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel, CH
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200 Philadelphia, PA 19104, US
DANA-FARBER CANCER INSTITUTE, INC. [US/US]; 450 Brookline Avenue Boston, MA 02215-5450, US
PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street Cambridge, MA 02138, US
BROGDON, Jennifer [US/US]; US (US)
CHANG, Hwai, Wen [US/US]; US (US)
ENGELS, Boris [NL/US]; US (US)
FREEMAN, Gordon, James [US/US]; US (US)
FREY, Gerhard, Johann [DE/US]; US (US)
MATARAZA, Jennifer, Marie [US/US]; US (US)
SINGH, Reshma [US/US]; US (US)
SHARPE, Arlene, Helen [US/US]; US (US)
Inventors:
BROGDON, Jennifer; US
CHANG, Hwai, Wen; US
ENGELS, Boris; US
FREEMAN, Gordon, James; US
FREY, Gerhard, Johann; US
MATARAZA, Jennifer, Marie; US
SINGH, Reshma; US
SHARPE, Arlene, Helen; US
Agent:
COLLAZO, Diana, M.; US
LU, David; US
GRANT, Angela, M.; US
KOYFMAN, Hannah, R.; US
Priority Data:
62/270,78022.12.2015US
Title (EN) MESOTHELIN CHIMERIC ANTIGEN RECEPTOR (CAR) AND ANTIBODY AGAINST PD-L1 INHIBITOR FOR COMBINED USE IN ANTICANCER THERAPY
(FR) RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE (CAR) CONTRE LA MÉSOTHÉLINE ET ANTICORPS CONTRE L'INHIBITEUR DE PD-L1 POUR UNE UTILISATION COMBINÉE DANS UNE THÉRAPIE ANTICANCÉREUSE
Abstract:
(EN) Provided are compositions for use in methods for treating diseases associated with expression of mesothelin comprising administering a cell that expresses a chimeric antigen receptor (CAR) specific to mesothelin in combination with a PD-L1 inhibitor.
(FR) L'invention concerne des compositions destinées à être utilisées dans des procédés de traitement de maladies associées à l'expression de la mésothéline, comprenant l'administration d'une cellule exprimant un récepteur d'antigène chimérique (CAR) spécifique de la mésothéline en combinaison avec un inhibiteur de PD-L1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP3393504US20190000944CN109069597